Navigation Links
Natural enzyme provides potential new approach for treating graft-vs.-host disease

ANN ARBOR, Mich. A natural enzyme derived from human blood plasma showed potential in significantly reducing the effects of graft-vs.-host disease, a common and deadly side effect of lifesaving bone marrow transplants.

Researchers from the University of Michigan Comprehensive Cancer Center looked at the drug alpha-1-antitrypsin, which is approved by the U.S. Food and Drug Administration for use in people who have a genetic mutation that makes them deficient in a certain enzyme. This drug has been used in many of these patients over extended periods of time and is known to cause minimal side effects.

More important, there are no known reports of increased susceptibility to infections. This is key for people with graft-vs.-host disease, where existing treatment options tend to suppress the immune system, putting patients at risk of infection. Graft-vs.-host disease is a major complication of bone marrow transplants using marrow from a donor, called an allogeneic transplant. This often-deadly side effect is what makes the procedure so risky.

"If we can get graft-vs.-host disease under control, we can more effectively use allogeneic bone marrow transplant to treat people with leukemia and lymphoma as well as other blood disorders. It would be a curative therapy for people who otherwise have no hope," says senior study author Pavan Reddy, M.D., associate professor of hematology/oncology at the U-M Medical School.

In this study, which appears in the Proceedings of the National Academy of Sciences, researchers used alpha-1-antitrypsin in mice that received allogeneic bone marrow transplants. The drug significantly reduced mortality from graft-vs.-host disease, compared to control mice who did not receive the drug.

In addition, alpha-1-antitrypsin reduced the number of inflammatory cells called T Effector cells that are known to be present in graft-vs.-host disease. It also increased the number of T-regulatory cells, which immunologists believe play a positive role in immune responses.

"It's likely the balance between the T-regulatory cells and the T Effector cells that leads to graft-vs.-host disease. Alpha-1-antitrypsin appears to have tipped that balance favorably," says lead study author Isao Tawara, M.D., Ph.D., a research investigator at the U-M Medical School.

The U-M researchers collaborated on this work with researchers from the University of Colorado and from Ben Gurion University of the Negev in Israel. The researchers are beginning to discuss a possible clinical trial using alpha-1-antitrypsin in post-transplant patients with graft-vs.-host disease for whom conventional therapies are no longer working.


Contact: Nicole Fawcett
University of Michigan Health System

Related medicine news :

1. Low levels of natural antibodies behind stroke
2. Whitemark Homes, Inc. Announces Corporate Update on Merger With Ribbon Naturals Corp.
3. Foamsource Introduces Natural Slumber 100% Natural Latex Mattresses & Toppers with Free Shipping
4. ThermaSkin Offers Free Natural Pepper Remedy To Acne Sufferers
5. Brooke Burke Named Spokeswoman for underWAY(TM), Americas First All Natural Appetite Suppressing Beverage & Thirst Quencher
6. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
7. Transcendental Meditation activates default mode network, the brains natural ground state
8. David Wolfe Hosts 3-Day Longevity Conference: Top Wellness Experts Reveal Tomorrow's Best Natural Health and Nutrition Information Today
9. Oram Plus Set to Take the Pain out of Gum Disease and Cavities, Naturally
10. Thrush Sufferers Seek Out Safe, Natural Remedies for Thrush, Driving a 237% Increase in Sales for "The 3 Day Thrush Cure"
11. 'Get Pregnant' Aims To Help Couples Conceive Naturally, Faster
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Scott ... one of a select few plastic surgeons in the New York City area ... SculpSure™ is the world’s first heat-induced laser treatment for fat loss in the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... provider of enterprise Time and Attendance/Workforce Management cloud-based solutions, announced today that ... Program with competencies in the Application Development, demonstrating a “best-in-class” ability and ...
(Date:11/30/2015)... MN (PRWEB) , ... November 30, 2015 , ... ... of a new product dealer. Joining more than 30 HealthPostures’ dealers located throughout ... foot space and increase the number of corporate, industrial, manufacturing and government workers ...
(Date:11/30/2015)... ... November 30, 2015 , ... CTI ... services which empower organizations through communication analytics, announced today that their Proteus® VoIP ... manage their service quality. , Proteus® VoIP QMS (Quality Management System) ...
(Date:11/29/2015)... St. Petersburg, FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal ... webstore. , It is the right time to get gifts for the skin care lover ... bow on top filled with serums . This year, the 3 serums are staples: Collagen, ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... IRVINE, Calif. and REHOVOT, Israel ... privately held specialty pharmaceutical company focused on acquiring and ... disorders, today announced the appointment of Keith A. ... directors. Gregory J. Flesher , chief executive ... experience in building successful organizations.  As chairman, he will ...
(Date:11/30/2015)... , November 30, 2015 ... Breast Care has entered into a multi-year agreement ... practice. This will allow Kentucky Breast Care to increase ... exceptional care for their patients. --> ... Breast Care has entered into a multi-year agreement ...
(Date:11/29/2015)... --  Royal Philips  (NYSE: PHG, AEX: PHIA) revealed a ... Radiological Society of North America Annual Meeting (RSNA), beginning ... Chicago . Visitors to the Philips ... of integrated Diagnostic Imaging, Clinical Informatics, Image Guided Therapy ... workflow and create a superior patient experience. ...
Breaking Medicine Technology: